Macimorelin Acetate Patent Expiration
Macimorelin Acetate is Used for diagnosing adult growth hormone deficiency. It was first introduced by Novo Nordisk Inc
Macimorelin Acetate Patents
Given below is the list of patents protecting Macimorelin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Macrilen | US6861409 | Growth hormone secretagogues |
Aug 01, 2022
(Expired) | Novo |
| Macrilen | US8192719 | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds | Oct 12, 2027 | Novo |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳